Cellular and Molecular Neurobiology

, Volume 33, Issue 7, pp 875–884

Neuromodulatory Propensity of Bacopa monniera Against Scopolamine-Induced Cytotoxicity in PC12 Cells Via Down-Regulation of AChE and Up-Regulation of BDNF and Muscarnic-1 Receptor Expression

Original Research


Scopolamine is a competitive antagonist of muscarinic acetylcholine receptors, and thus classified as an anti-muscarinic and anti-cholinergic drug. PC12 cell lines possess muscarinic receptors and mimic the neuronal cells. These cells were treated with different concentrations of scopolamine for 24 h and were protected from the cellular damage by pretreatment with Bacopa monniera extract (BME). In current study, we have explored the molecular mechanism of neuromodulatory and antioxidant propensity of (BME) to attenuate scopolamine-induced cytotoxicity using PC12 cells. Our results elucidate that pretreatment of PC12 cells with BME ameliorates the mitochondrial and plasma membrane damage induced by 3 μg/ml scopolamine to 54.83 and 30.30 % as evidenced by MTT and lactate dehydrogenase assays respectively. BME (100 μg/ml) ameliorated scopolamine effect by down-regulating acetylcholine esterase and up-regulating brain-derived neurotropic factor and muscarinic muscarinic-1 receptor expression. BME pretreated cells also showed significant protection against scopolamine-induced toxicity by restoring the levels of antioxidant enzymes and lipid peroxidation. This result indicates that the scopolamine-induced cytotoxicity and neuromodulatory changes were restored with the pretreatment of BME.


Scopolamine Bacopa monniera PC12 cells Gene expression Acetylcholine esterase Antioxidant enzymes 


  1. Aebi H (1984) Catalase in vitro. Meth Enzymol 105:121–126PubMedCrossRefGoogle Scholar
  2. Anand T, Naika M, Swamy MSL, Khanum F (2011) Antioxidant and DNA damage preventive properties of Bacopa monniera (L.) Wettst. Free Rad Antiox 1:84–90CrossRefGoogle Scholar
  3. Anand T, Phani Kumar G, Pandareesh MD, Swamy MSL, Khanum F, Bawa AS (2012) Effect of bacoside extract from Bacopa monniera on physical fatigue induced by forced swimming. Phytother Res 26:587–593PubMedCrossRefGoogle Scholar
  4. Anand T, Bhanu Prakash K, Pandareesh MD, Khanum F (2013) Development of bacoside enriched date syrup juice and its evaluation for physical endurance. J Food Sci Technol. doi:10.1007/s13197-013-0955-5 Google Scholar
  5. Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer’s disease and the basal forebrain cholinergic system: relations to beta amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68:209–245PubMedCrossRefGoogle Scholar
  6. Aykaç G, Uysal M, Yalçin AS, Koçak-Toker N, Sivas A, Oz H (1985) The effect of chronic ethanol ingestion on hepatic lipid peroxide, glutathione, glutathione peroxidase and glutathione transferase in rats. Toxicology 36:71–76PubMedCrossRefGoogle Scholar
  7. Barak S, Weiner I (2009) Towards an animal model of an antipsychotic drug resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs. Int J Neuropsychopharmacol 12:227–241PubMedCrossRefGoogle Scholar
  8. Bartus RT, Dean RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–414PubMedCrossRefGoogle Scholar
  9. Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S (2000) Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytother Res 14:174–179PubMedCrossRefGoogle Scholar
  10. Braida D, Paladini E, Griffini P, Lamerti M, Maggi A, Sala M (1996) An inverted U-shaped curve for heptyl-physostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. Eur J Pharmacol 302:13–20PubMedCrossRefGoogle Scholar
  11. Bramham CR, Messaoudi E (2005) BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 76:99–125PubMedCrossRefGoogle Scholar
  12. Bronillette J, Young D, Quirion R (2007) Hippocampal gene expression profiling reveals the possible involvement of Homer 1 and GABAB receptors in scopolamine induced amnesia. J Neurochem 102:1978–1989CrossRefGoogle Scholar
  13. Brown JH (1990) Atropine, scopolamine, and related anti-muscarinic drugs. In: Goodmaann and Gilman’s (eds) The pharmacological basis of therapeutics, 8th edn. Pergamon Press, New York, pp 150–165Google Scholar
  14. Buege JA, Aust SD (1978) Microsomal lipid peroxidation. Methods Enzymol 52:301–310Google Scholar
  15. Channa S, Dar A, Anjum S, Yaqoob M, Rahman A (2006) Anti-inflammatory activity of Bacopa monniera in rodents. J Ethnopharmacol 104:286–289PubMedCrossRefGoogle Scholar
  16. Chowdhuri DK, Parmar D, Kakkar P, Shukla R, Seth PK, Srimal RC (2002) Antistress effects of bacosides of Bacopa monnieri: modulation of Hsp70 expression, superoxide dismutase and cytochrome P450 activity in rat brain. Phytother Res 16:639–645PubMedCrossRefGoogle Scholar
  17. Cunha C, Angelucci A, D’Antoni A, Dobrossy MD, Dunnett SB, Berardi N, Brambilla R (2009) Brain-derived neurotrophic factor (BDNF) over expression in the forebrain results in learning and memory impairments. Neurobiol Dis 33:358–368PubMedCrossRefGoogle Scholar
  18. Das A, Shanker G, Nath C, Pal R, Singh S, Singh H (2002) A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba: anticholinesterase and cognitive enhancing activities. Pharmacol Biochem Behav 73:893–900PubMedCrossRefGoogle Scholar
  19. Dash VB, Kashyap VL (1980) Materia medica of ayurveda. Concept Publishing Company, New Delhi, pp 53–54Google Scholar
  20. Dawson GR, Bentley G, Drapper F, Rycroft W, Iversen SD, Pagella PG (1991) The behavioral effects of heptyl-physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents. Pharmacol Biochem Behav 39:865–871PubMedCrossRefGoogle Scholar
  21. Dhanasekharan M, Tharakan B, Holcomb LA, Hitt AR, Young KA, Manyam BV (2007) Neuroprotective mechanisms of ayurvedic antidementia botanical Bacopa monniera. Phytother Res 21:965–969CrossRefGoogle Scholar
  22. Dhawan BN, Singh HK (1996) Pharmacological studies on Bacopa monnieri an ayurvedic nootropic agent. Eur Neuropsychopharmacol 3:144–150CrossRefGoogle Scholar
  23. Ding Q, Dimayuqa E, Keller JN (2007) Oxidative damage, protein synthesis, and protein degradation in Alzheimer’s disease. Curr Alzheimer Res 4:73–79PubMedCrossRefGoogle Scholar
  24. Ebert U, Kirch W (1998) Scopolamine model of dementia: electro encephalogram findings and cognitive performance: E. J Clin Invest 28:944–949CrossRefGoogle Scholar
  25. Ellman GL, Courtney KD, Andre V Jr, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholine esterase activity. Biochem Pharmacol 7:88–95PubMedCrossRefGoogle Scholar
  26. El-Sherbiny DA, Khalifa AE, Attia AS, Eel-D E (2003) Hypericum perforatum extract demonstrates antioxidant properties against elevated rat brain oxidative status induced by amnesic dose of scopolamine. Pharmacol Biochem Behav 76:525–533PubMedCrossRefGoogle Scholar
  27. Ernst E (2006) Herbal remedies for anxiety - a systematic review of controlled clinical trials. Phytomedicine 13:205–208PubMedCrossRefGoogle Scholar
  28. Felder CC, Bymaster FP, Ward J, DeLapp N (2000) Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem 43:4333–4353PubMedCrossRefGoogle Scholar
  29. Gottmann K, Mittmann T, Lessmann V (2009) BDNF signaling in the formation, maturation and plasticity of glutamatergic and GABAergic synapses. Exp Brain Res 199:203–234PubMedCrossRefGoogle Scholar
  30. Halliwell B, Gutteridge JM (1989) Free radicals in biology and medicine. 2nd edn. Clarendron Press, OxfordGoogle Scholar
  31. Holcomb LA, Dhanasekharan M, Hitt AR, Young KA, Rigs M, Manyam BV (2006) Bacopa monniera extract reduces amyloid levels in PSAPP mice. J Alzheimer’s Dis 9:243–251Google Scholar
  32. Howells DW (2000) Reduced BDNF mRNA expression in the Parkinson’s disease substantia nigra. Exp Neurol 166:127–135PubMedCrossRefGoogle Scholar
  33. Hulme EC, Birdsall NJ, Burgen AS, Mehta P (1978) The binding of antagonists to brain muscarinic receptors. Mol Pharmacol 14:737–750PubMedGoogle Scholar
  34. Jimenez–Jimenez FJ, Alonso-Navarro H, Avuso-Peralta L, Jabbour-Wadih T (2006) Oxidative stress and Alzheimer’s disease. Rev Neurol 42:419–427PubMedGoogle Scholar
  35. Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 28:10422–10433PubMedCrossRefGoogle Scholar
  36. Kishore K, Singh M (2005) Effect of bacosides, alcoholic extract of Bacopa monniera Linn. (brahmi), on experimental amnesia in mice. Ind J Exp Biol 43:640–645Google Scholar
  37. Klinkenberg I, Blokland A (2011) A comparison of scopolamine and biperiden as a rodent model for cholinergic cognitive impairment. Psychopharmacology (Berl) 215:549–566CrossRefGoogle Scholar
  38. Lebois EP, Bridges TM, Lewis LM, Dawson ES, Kane AS, Xiang Z, Jadhav SB, Yin H, Kennedy JP, Meiler J, Niswender CM, Jones CK, Conn PJ, Weaver CD, Lindsley CW (2010) Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. ACS Chem Neurosci 1:104–121PubMedCrossRefGoogle Scholar
  39. Lee SM, Yoon MY, Park HR (2008) Protective effects of Paeonia lactiflora pall on hydrogen peroxide-induced apoptosis in PC12 cells. Biosci Biotech Biochem 72:1272–1277CrossRefGoogle Scholar
  40. Lowry OH, Rosenberg NJ, Farr AL, Randal RJ (1951) Protein measurement with Folin phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
  41. Massoud F, Gauthier S (2010) Update on the pharmacological treatment of Alzheimer’s disease. Curr Neuropharmacol 8:69–80PubMedCrossRefGoogle Scholar
  42. Mates JM (2000) Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 153:83–104PubMedCrossRefGoogle Scholar
  43. Murer MG, Yan Q, Raisman-Vozari R (2001) Brain-derived neurotrophic factor in the control human brain and in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol 63:71–124PubMedCrossRefGoogle Scholar
  44. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358PubMedCrossRefGoogle Scholar
  45. Renner UD, Oertel R, Kirch W (2005) Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit 27:655–665PubMedCrossRefGoogle Scholar
  46. Roberta RE, Nicoletta P, Anna P, Ananth P, Yang M, Catherine RE (1999) Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Rad Biol Med 26:1231–1237CrossRefGoogle Scholar
  47. Russo A, Izzo AA, Borrelli F, Renis M, Vanella A (2003) Free radical scavenging capacity and protective effect of Bacopa monniera L. on DNA damage. Phytother Res 17:870–875PubMedCrossRefGoogle Scholar
  48. Saraf MK, Prabhakar S, Kanduja KL, Anand A (2011) Bacopa monniera attenuates scopolamine-induced impairment of special memory in mice. Evid Based Complement Alternat Med 236186:1–10CrossRefGoogle Scholar
  49. Schmeller T, Sporer F, Sauerwein M, Wink M (1995) Binding of tropane alkaloids to nicotinic and muscarinic acetylcholine receptors. Pharmazie 50:493–495PubMedGoogle Scholar
  50. Schmittgen TD, Zakrajsek BA (2000) Effect of experiment treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods 46:69–81PubMedCrossRefGoogle Scholar
  51. Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, Jadhav SB, Menon UN, Xiang Z, Watson ML, Christian EP, Doherty JJ, Quirk MC, Snyder DH, Lah JJ, Levey AI, Nicolle MM, Lindsley CW, Conn PJ (2009) A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci 29:14271–14286PubMedCrossRefGoogle Scholar
  52. Sies H (1986) Biochemistry of oxidative stress. Angew Chem Int Ed Engl 25:1058CrossRefGoogle Scholar
  53. Singh HK, Dhawan BN (1992) Drugs affecting learning and memory. Wiley Eastern, New Delhi, pp 189–207Google Scholar
  54. Singh HK, Dhawan BN (1997) Neuropsychopharmacological effects of the ayurvedic nootropic Bacopa monniera Linn. (Brahmi). Ind J Pharmacol 29:359–365Google Scholar
  55. Tan YL, Zhou DF, Zhang XY (2005) Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 74:260–270CrossRefGoogle Scholar
  56. Tripathi YB, Chaurasia S, Tripathi E, Upadhyay A, Dubey GP (1996) Bacopa monniera Linn. as an antioxidant: mechanism of action. Ind J Exp Biol 34:523–526Google Scholar
  57. Xu B, Gottschalk W, Chow A (2000) The role of brain derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving trkB. J Neurosci 20:6888–6897PubMedGoogle Scholar
  58. Yamada K, Nabeshima T (2003) Brain-derived neurotrophic factor/TrkB signaling in memory processes. J Pharmacol Sci 91:267–270PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Biochemistry and Nanosciences Discipline, Defence Food Research LaboratoryMysoreIndia

Personalised recommendations